BioNeutral, KRP complete manufacturing and distribution agreement

NewsGuard 100/100 Score

BioNeutral Group Inc., (OTCBB:BONU) a specialty chemical technology-based life science company, announced today that it completed an agreement with Keystone Research and Pharmaceuticals ("KRP") www.krandp.com for its proprietary formulations for use in the Veterinary, Dental and Cosmetic markets. The Terms are being held confidential.

Under the terms of the agreement BioNeutral will contribute products, knowhow and access to its Chief Scientist Dr. Andy Kielbania to help produce, promote and sell BioNeutral products in the above mentioned markets globally. BioNeutral will use Keystone Industries as its exclusive Manufacturer. KRP will provide free rent at its Germany plant for one year. KRP will give BioNeutral access to its Chief Scientist Larry Steffier and to its distributors and distribution network and include BioNeutral products at tradeshows and feature BioNeutral products in KRP's promotional literature. KRP will be spending at least $100,000 in the first year on equipment, developing production processes, marketing research, sales development and personnel.

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: "We are pleased to be working with Keystone Industries. Their excellent track record in manufacturing, innovative technology and knowledge of the market are important attributes to this agreement."

Source:

 BioNeutral Group Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles